Intranasal Foralumab for Multiple Sclerosis Now Approved by FDA for At-Home Dosing
The FDA’s decision to allow at-home dosing of intransal foralumab for patients with multiple sclerosis is likely to improve patient compliance to treatment and health outcomes, according to a recent release statement.
Autonomic Symptom Burden and Decreased Quality of Life Among Patients With MS and NMOSD
Researchers in Serbia identified link between autonomic symptom burden and quality of life.
2 Clarke Drive Cranbury, NJ 08512